Tentarix targets completion of AbbVie, Gilead partnered programs within 12 months
ABBV•Tentarix targets completing its partnered programs with AbbVie and Gilead within roughly 12 months. Its internal pipeline is advancing toward the clinic, with several discovery-stage programs moving toward IND-enabling studies.




